06/06/2017

NCCN has published updates to the NCCN Guidelines® and NCCN Compendium® for Bladder Cancer.

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Bladder Cancer. These NCCN Guidelines^® are currently available as Version 5.2017. 

• Principles of Systemic Therapy
  • First-line chemotherapy for locally advanced or metastatic disease
    • For cisplatin ineligible, “Pembrolizumab” was added as a standard option with a category 2A designation for:
      • Bladder cancer
      • Upper GU tract tumors: Renal pelvis
      • Upper GU tract tumors: Urothelial carcinoma of the ureter
      • Urothelial carcinoma of the prostate
      • Primary carcinoma of the urethra (urothelial carcinomas only)

For your reference, the previous update (Version 4.2017) to the NCCN Guidelines for Bladder Cancer, published on May 17, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.